BACKGROUND: The @entity2290 ( @entity2290 ) system has been involved in @entity3 and in metastasis. @entity2290 activity is controlled by its principal inhibitor, the @entity2289 ( @entity2289 ), but it can also be inhibited by @entity10854 . Increased levels of @entity2290 and @entity2289 are known to be associated with a poor prognosis in @entity0 . To our knowledge this is the first study of the expression and role of @entity10854 in @entity1 @entity0 tissue. MATERIALS AND METHODS: Protein and mRNA levels were evaluated for @entity2290 , @entity2289 and @entity10854 in @entity0 tissues from 70 different @entity1 . The localization of antigen and mRNA of these proteins was studied by immunohistochemistry and in situ hybridization, respectively. RESULTS: No significant differences were observed for @entity10854 mRNA or protein levels between the nodal status groups or the different post-surgical @entity5 -node-metastasis (pTNM) stages. However, @entity2290 and @entity2289 mRNA and antigen levels significantly increased at the pTNM stage and in node-positive @entity1 . @entity10854 antigen levels were significantly higher in early relapse-free @entity1 , whereas @entity2289 antigen levels were significantly higher in @entity1 who suffered a relapse. @entity10854 protein and mRNA were localized in stromal cells. @entity2289 and @entity2290 protein were detected in @entity5 , endothelial and stromal cells and their mRNA mainly in stromal cells. CONCLUSIONS: Our results indicate that @entity10854 is expressed in @entity1 @entity0 tissues, and that elevated levels of @entity10854 could be a positive prognostic factor in this disease. A potential mechanism for the contribution of @entity10854 to a positive long-term outcome may involve suppression of @entity5 invasion through protease inhibition in stroma.

Expression of plasminogen activator inhibitors type 1 and type 3 and XXXX protein and mRNA in @entity0 .

@entity1 :: ('9606', 'Species') :: ['human', 'patients'] @entity2290 :: ('5328', 'Gene') :: ['urokinase plasminogen activator', 'uPA'] @entity2289 :: ('5054', 'Gene') :: ['PAI-1', 'PA inhibitor type-1'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer'] @entity3 :: ('MESH:D009362', 'Disease') :: ['cancer cell invasion'] @entity10854 :: ('5104', 'Gene') :: ['PAI-3']
@entity2290 :: (5328,Gene) :: ['urokinase plasminogen activator']
